Testosterone Pellets Explained

Testosterone pellets are small cylinders of crystalline testosterone that a clinician places under your skin, where they dissolve over months. Each Testopel pellet measures 3.2 mm across and about 9 mm long, weighs roughly 78 mg, and carries 75 mg of testosterone with stearic acid and povidone as the only other ingredients. There is no oil, no carrier gel, nothing to rub in and nothing to inject. The hormone leaves by slow surface dissolution, which is why the dose is fixed at the moment of insertion.

Absorption is front-loaded rather than flat. The label describes roughly one third of the material absorbed in the first month, one fourth in the second and one sixth in the third, with adequate effect usually continuing three to four months and sometimes as long as six. Surface area drives that curve as much as total milligrams: a 2025 open study found smaller pellets at a lower total dose produced higher blood levels and fewer extrusions than a larger dose packed into fewer pellets.

The insertion is a minor surgical procedure done in a treatment room. The skin is cleaned and numbed, a small incision is made over the upper outer buttock or flank, and a trocar pushes the pellets into the fat layer along a track angled away from the opening. The AUA lists the usual regimen as six to twelve 75 mg pellets every three to four months, placed subcutaneously in the buttock or flank, with bloodwork at two and twelve weeks after each insertion. The visit itself takes minutes.

This is the single biggest practical difference between pellets and every other testosterone route, and it is the reason a telehealth visit alone cannot deliver them. A gel or a vial ships to your door and you handle the dose yourself. A pellet needs sterile technique, a trocar and someone trained to use it, three or four times a year.

Any online service that offers pellets has to hand you to a physical clinic for the procedure.

A six-institution pooled analysis of 380 men across 702 insertions found that six to ten or more pellets, 450 mg and up, brought total testosterone into the therapeutic range by one month and sustained it above 300 ng/dL for four to six months, with eight or more pellets giving the best peak levels and the longest effect. That is retrospective pooled practice data rather than a randomized trial, so read it as what happened in six clinics, not as proof of a dose.

An open-label study of fifteen men given twelve pellets, 900 mg, measured hormones by mass spectrometry on eight occasions and saw total testosterone swing between roughly 300 and 1,000 ng/dL over the first two weeks before settling and remaining at or above 300 ng/dL through day 113.

One extrusion and one case of polycythemia occurred in that group of fifteen. Fifteen men, no control arm, and the authors say plainly that this limits what the numbers mean.

The label is unusually blunt about this. It states that pellet implantation is much less flexible for dosage adjustment than oral or intramuscular routes, that great care should be used in estimating the amount of testosterone needed, and that where the effects of testosterone have to be discontinued, the pellets would have to be removed. Removal means reopening the site and retrieving objects the size of a grain of rice out of tissue they have partly dissolved into.

Put a number on what that costs you. A gel stops tonight and washes off in a shower. A short-acting injection fades over one to two weeks. A pellet insertion commits you for three to six months, and the standard bloodwork sits at two and twelve weeks, so a rising hematocrit or a mood change caught at week twelve can still have a quarter of its course to run with no way to turn it down. That asymmetry is the honest trade.

A single-site retrospective review of 80 men across 292 Testopel procedures reported one implant site infection, 0.3%, and one extrusion, 0.3%, against historical rates of 1.4 to 6.8% for infection and 8.5 to 12% for extrusion with the older Organon pellet. Cavender and Fairall credited the smaller, smooth-surfaced pellet and the implantation technique, and noted that nobody who followed the post-procedure instructions had either complication.

Technique moves these numbers more than the product does. Conners and colleagues compared a single straight track against a two-track V approach across 281 procedures in 168 men: extrusion fell from 7.5% to 0.8%, infection from 5% to 1.2%, and pain severe enough to stop therapy from 7.5% to 1.7%, while hematoma appeared in 1.2% of V-technique cases and in none of the standard ones. Only one of the three hematomas was in someone on a blood thinner.

The six-institution series logged four extrusions and three hematomas across its 702 insertions, and the label's post-marketing section lists implant site infection and extrusion together with induration, inflammation, fibrosis, bleeding, bruising, wound drainage, pain and itching, most of it inside the first month after implantation. These are observational series rather than randomized comparisons, so the spread between them reflects clinics as much as it reflects the drug.

The AUA table lists short and long-acting injections at 50 to 200 mg every 7 to 14 days into muscle, daily gels, and pellets every three to four months. Injections produce the sharpest early peaks, and the guideline points to those supra-physiological early levels as the likely reason injectable testosterone drives the largest rises in hemoglobin and hematocrit. Gels avoid the peaks but demand a daily habit and a drying window.

Pellets suit you if the daily or fortnightly routine is what keeps breaking down, or if transference to a partner or a child is a real concern in your home, which the AUA treats seriously enough to make discussing it a strong Grade A recommendation. They suit you badly if your dose is still being titrated, if you bruise or bleed easily, if you may want children in the next year or two, or if you want the option to stop quickly. Sorting which of those describes you is a job for the clinician who prescribes, with your labs and your history in front of them.

Every route of testosterone thickens blood. The AUA gives its strongest Grade A recommendation that hemoglobin and hematocrit be measured before therapy begins, defines polycythemia as a hematocrit above 52%, advises withholding testosterone when the baseline hematocrit exceeds 50% until the reason is explained, and states that a hematocrit of 54% or more on treatment warrants intervention, with rechecks every six to twelve months.

Route changes the size of the risk. In a comparative series of 175 men, 19% of those on intramuscular testosterone developed polycythemia against 12.5% on pellets and 5.4% on gels. The middle position sounds reassuring until you pair it with the previous section: first-line management for a high hematocrit is lowering the dose, and there is no dose to lower while the pellets are still dissolving. Twelve pellets produced one case of polycythemia among fifteen men in the 900 mg study.

TRAVERSE enrolled 5,246 men aged 45 to 80 with existing or high cardiovascular risk and two fasting testosterone readings below 300 ng/dL, randomizing them to daily 1.62% transdermal testosterone gel or placebo gel. A primary event occurred in 7.0% on testosterone and 7.3% on placebo, a hazard ratio of 0.96 that met the trial's noninferiority margin. Atrial fibrillation, acute kidney injury and pulmonary embolism were each more common in the testosterone arm.

On 28 February 2025 the FDA issued class-wide labeling changes: it added the TRAVERSE results, removed the boxed warning language about increased risk of adverse cardiovascular outcomes, retained the limitation of use for age-related hypogonadism, and added a warning on increased blood pressure after ambulatory monitoring studies confirmed a class-wide effect. Read the boundary carefully. TRAVERSE tested a gel. The current Testopel label, revised July 2025, still records that long-term trials have not been conducted to assess cardiovascular outcomes, still calls the evidence inconclusive, and now carries the blood pressure warning.

That February 2025 picture has since moved again. In June 2026 the FDA requested a further round of prescribing information updates across testosterone products, removing the limitation of use which said safety and efficacy had not been established in men with age-related hypogonadism, and revising the safety information covering prostate cancer and benign prostatic hyperplasia. A request is not the same as a label you can read today. Labels turn over product by product, so the carton in front of you may still carry wording the agency has already asked to drop, and the revision date on that label is the only way to tell which version you have.

Testosterone you did not make yourself suppresses the pituitary signaling that keeps sperm production running. The AUA makes it a strong Grade A statement that exogenous testosterone should not be prescribed to men who are currently trying to conceive, and a separate strong Grade A recommendation that the long-term effect on spermatogenesis be discussed with anyone interested in future fertility. Oligospermia at higher doses sits in the label's own adverse reactions list. The recovery data is reassuring and slow at once. An integrated analysis of 30 hormonal male contraception studies covering 1,549 healthy men found a median 3.4 months to recover a sperm concentration of 20 million per mL, with 67% recovered by six months, 90% by twelve, 96% by sixteen and 100% by twenty-four, and faster recovery in those on shorter-acting testosterone preparations. Pellets are among the longest-acting.

The AUA notes hCG, SERMs or aromatase inhibitors as options where fertility has to be preserved.

No dollar figure appears on this page, because pellet pricing is set clinic by clinic and pellet by pellet and there is no live, verifiable national source for it that we are willing to quote. The structure is knowable in advance though. The bill splits into the pellets, charged by quantity, and the implantation procedure itself. The pellet has its own HCPCS drug code, listed as testosterone pellet 75 mg, which is the detail worth quoting when you ring your insurer.

Because cost scales with count, and six to twelve pellets is the usual range, asking what an insertion costs is the wrong question. Ask how many pellets they plan to place, what each one costs and what the procedure fee is. Whether pellets fit you at all is a clinician's decision, and nothing here is medical advice. What you can do is ask the clinical questions: which insertion technique they use, whether they schedule the two and twelve week bloodwork, what they do if your hematocrit crosses 54%, and whether fertility has been discussed.